您使用提示模式 关闭

Regeneron, ordinary share
US75886F1075, REGN

添加股票到 WL
Regeneron, 国家 — 美国
不存在此交易信息
数据显示法可以选择 图形 | 表格
信息来源 - PJSC“莫斯科交易所”。未经PJSC“莫斯科交易所”授权, 禁止传播一切相关证券信息。版权所有, 违法必究。
信息来源 - PJSC“莫斯科交易所”。未经PJSC“莫斯科交易所”授权, 禁止传播一切相关证券信息。版权所有, 违法必究。
ADD-IN
Cbonds 加载项
API
债券数据 API
请求认证
需要 访问
在数据库中超过2500个条目, 请细化您的搜索范围
所选期间没有数据

最新价格

探索最全面的数据库

80 万

债券

超过 400

定价来源

8 万

股票

9 千

ETF

以最有效的方式跟踪您的投资组合
债券筛选器
观察列表
Excel 附加组件

发行人

简介
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA ...
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.
  • 发行人
  • 发行人 / 借款人全称
    Regeneron Pharmaceuticals Inc
  • 行业
    药品生产和生物技术

股票指数

你必须 注册 才能获得访问权